SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 55.26+1.2%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Michael Young who wrote (4942)11/16/2001 9:46:47 AM
From: Biomaven  Read Replies (2) of 52153
 
The key to KOSP is getting the co-promotion deal sorted out, either with BMY or someone else. I was disappointed that they weren't able to do this ahead of the merger closing, as normally that is where they would have the most leverage.

KOSP is a very different company than those Asensio normally attacks. If KOSP can get the marketing arrangements sorted out favorably, Asensio will get buried. It's worth noting that Niaspan has been consistently growing at twice the rate to of the overall market, and now has a $100m run rate, which is good for a low-priced product.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News